[Recombinant Oka varicella vaccine as a live hepatitis B virus vaccine].
Recombinant Oka varicella-hepatitis B virus (HBV) vaccine was constructed by inserting the HBV surface antigen (HBsAg) gene coding partial PreS2 and whole S regions into the viral thymidine kinase gene. HBsAg was expressed in the cytoplasm of infected cells. Intracellular HBsAg (26K and 30K) was N- and O-glycosylated, sialylated, and secreted into the supernatant as 30K and 35K HBsAg particles. Recombinant virus induced antibody response to both varicella-zoster virus and HBsAg in guinea pigs and the level of antibody titers to HBsAg was comparable in guinea pigs immunized with a live varicella-HBV vaccine or commercial HBs subunit vaccine. Altogether, this recombinant virus may be a good candidate for the live varicella-HBV vaccine.
Department of Virology, Toyama Medical and Pharmaceutical University.
K
K
Shiraki
T
T
Takahara
D000818:Animals; D006168:Guinea Pigs; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D013937:Thymidine Kinase / Q000235:genetics; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D013937:Thymidine Kinase